At the end of 2016, the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (8 th edition) was published. The anatomic and prognostic stage groups were defined in the section on breast cancer. In the prognostic stage group, the stages were identified by using T, N, and M, as well as ER, PR, HER2, and tumor-grade biomarkers. In addition, patients in T1-2, N0, M0, grades 1-3 and those with ER (+), HER2 (−), and Oncotype DX recurrence score <11 were classified as stage IA. A year later, in the light of new data, the breast cancer section of the AJCC manual (8 th edition) was updated. This review aims to reveal the changes in the stages of our institutional breast cancer patients according to the first and updated versions of the AJCC manual (8 th edition) and to compare the clinical reflections with the help of staging studies with regard to the manual. According to the pathological prognostic stage data, patients mostly display downstaging.
Introduction
The first TNM system for breast cancer was developed in 1959. There was limited information available regarding the biology of breast cancer at that time, and there was no effective systemic treatment available. Today, parameters such as the tumor grade, estrogen receptor (ER), progesterone receptor (PR), and HER2 status are known to have predictive and prognostic importance. At the end of 2016, the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (8th edition) was published. [1] Anatomic and prognostic stage groups were defined in the section on breast cancer. In the prognostic stage group, the stages were identified by using T, N, and M, as well as ER, PR, HER2, and tumor-grade biomarkers. In addition, patients in T1-2, N0, M0, and grades 1-3 and those with ER (+), HER2 (−), and Oncotype DX recurrence score <11 were classified in stage IA. A year later, in the light of new data, the section on breast cancer in this manual was updated. [2] Although the basic principles did not change, stages involving clinical and pathological prognoses were added in addition to the anatomic stage. There were no changes in the anatomic stage for breast cancer in the first and the updated manuals.
This review aims to reveal the changes in the stages of our institutional breast cancer patients according to the first and the updated versions of the AJCC manuals and to compare the clinical reflections with the help of stage studies involving the updated manual. Table 1 .
Stage Changes According to the First and Updated
One of the most remarkable points is that in the first version of the manual, 50 (14.2%) patients had no prognostic stage; however, in the updated version, all and 2006 were considered. Data involving T, N, M, ER, PR, HER2, and tumor grade were noted in accordance with the section on breast cancer of the AJCC manual (8th edition). The histological grade of the tumor was evaluated according to the Elston-Ellis modification of the Scarff-Bloom-Richardson grading system. [3] The ER biomarkers were determined by immunohistochemistry and were recorded as the percentage of cells stained as positive. The cut-off of 1% was used for the treated patients, which was consistent with the changes in the American Society of Clinical Oncology (ASCO) guidelines. [4] The PR status was determined by immunohistochemistry, and staining of 1% of the cells or more was considered to be positive for PR. HER2 status was defined as positive if the score was 3+ on immunohistochemistry or fluorescence in situ hybridization, demonstrating gene amplification. [5] Because the anatomic stage did not change in the first and the updated versions of the AJCC manuals, all the patients were staged according to the anatomic stage, prognos- the patients had a pathological prognostic stage. The other point is that in the first and the updated versions, the patients were downstaged as compared to the anatomic staging system. However, downstaging was more prominent in the updated version than that in the first version. The degrees of stage migration are listed in Table 2 . Oncotype DX multigene analysis was appropriate in 97 patients (27.5%). Oncotype DX assay was not performed in this series. Regardless of the Oncotype DX recurrence score, out of the 97 patients, 46 (47.4%) would still be in stage IA in the first version and 83 (85.6%) would still be in stage IA in the updated version (Table 3) .
Focusing on Stage Changes with the Help of Latest Studies
The prognostic stage in breast cancer was developed using the National Cancer Database (NCDB) consisting of approximately 238.000 patients' data, who were diagnosed and treated between 2010 and 2011 and whose clinical information can be accessed, including AJCC TNM staging, tumor grade, ER, PR, and HER2 biomarkers. The prognostic subgroup and survival calculations were performed according to the TNM stage, tumor grade, ER, PR, and HER2 statuses. On the basis of these analyses, 170 different prognostic groups-defined on the basis of tumor biology, varying in TNM stages-were distributed between the stages of 0 and IV. At the end of 2016, the 8th edition of the manual was published. [1, 6] After the publication of this update, the prognostic stage was validated in additional cohorts. [7] [8] [9] [10] [11] [12] [13] The anatomic and prognostic stage analyses of the updated manual in breast cancer subgroups was performed on five of these studies [8] [9] [10] 13] and the general group involving non-metastatic invasive breast cancer patients was analyzed on three of them. [ In December 2017, the section on breast cancer of the AJCC manual (8 th edition) was updated in the light of new data. Two analyses were performed on the NCDB data. In the first case, the clinical information of all the patients who showed the clinical prognostic stage was used. In that study, 334.000 patients who were diagnosed with invasive breast cancer between 2010 and 2012 and the median follow-up period of 41.7 months were evaluated. All the patients were included in this analysis, regardless of the treatment, because most of them received systemic treatment on the basis of their stages and biomarkers. The clinical prognostic stage was recommended for all the patients. The second analysis was limited to the patients with surgical resections as the initial treatment. Patients who received preoperative systemic therapy or radiotherapy (neoadjuvant therapy) were excluded from this analysis; all the remaining patients were included, regardless of the treatment received by them after surgery. Approximately 306.000 patients whose median follow-up period was 42.3 months and diagnosed between 2010 and 2012 were included in this analysis. Pathological prognostic staging should be calculated in patients undergoing surgery as the initial treatment. Pathological prognostic stage groups were established by combining the anatomic stage groups with the grade, ER, PR, and HER2 statuses. Here, 120 different patient categories were revealed in this way.
In the first version as well as in the updated version of the AJCC manual (8 th edition), patients in T1-2, N0, M0, grades 1-3 and those with ER (+), HER 2(−), and Oncotype DX recurrence score <11 were classified as stage IA. [2] In almost all the studies, Oncotype DX multigene assay results were reported as "does not exist. " In our institutional series, there were 97 (27.5%) patients appropriate for Oncotype DX In particular, according to the anatomic stage, an increase in stage IB was detected, whereas an increase in stage IA was also detected according to the first version of the AJCC manual (8 th edition). In our institutional series, it is revealed that downstaging increases in relation to the pathological prognostic staging system. In patients who require Oncotype DX multigene analysis, it can be emphasized that it would still be stage IA at the rate of 85.6%, independent of the Oncotype DX multigene score.
Conclusion
In the treatment of breast cancer, tumor biomarkers have been taken into consideration for decades and they facilitate the determination of the way of treatment. Breast cancer staging is no longer limited to anatomical findings, but it can be associated with the tumor grade, ER, PR, and HER2 statuses. The rapid change in the staging systems in the last year seems to lead us to patient-oriented treatments for breast cancer in the future. According to the pathological prognostic stage data, patients mostly display downstaging. Results from further studies may reveal whether a particular patient group may require Oncotype DX shrink or not, and how to use the information from other multigene analyses (MammaPrint, Prosigna, Breast Cancer Index, EndoPredict, etc.) in clinical decision-making in breast cancer patients.
